Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals. • 612-624-2620 • 1-888-226-2376

Leukemia Clinical Trials

Protocol Number Title
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
MT2001-10 Allogeneic Bone Marrow Transplant Using Less Intensive Therapy
MT2003-15 Use of Cyclophosphamide/Fludarabine to Promote in vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy after Allogeneic Transplant
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
MT2004-24 Autologous Peripheral Blood Stem Cell Transplant for Patients with Lymphoma
MT2006-01 Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+ CD4+ T-Regulatory (Treg) Cells After Non-Myeloablative Cord Blood Transplantation
MT2006-24 Total Marrow Irradiation and Myeloablative Chemotherapy Followed by Double Umbilical Cord Blood Transplantation in Patients with Refractory Acute Leukemia
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples.
MT2009-15 Lymphodepleting Chemotherapy with Rituximab and Allogeneic Natural Killer Cells for Patients with Refractory Lymphoid Malignancies
MT2009-22R Monitoring of Immune Function and Minimal Residual Disease in Patients and Donors After Hematopoietic Cell Transplantation (HCT)
Hematologic Malignancy Tissue Bank Formerly: "Leukemia, Lymphoma and MDS Tissue Bank" Formerly: "Leukemia and MDS Tissue Bank" & "Pediatric Leukemia Tissue Bank"
Childhood Cancer Survivor Study
HM2010-05 Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 In Patients with Advanced Leukemia
MT2010-10 Haploidentical Donor Natural Killer (NK) Cell Infusion with Intravenous Recombinant Human IL-15 (rhIL-15) in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)
MT2010-12: A First-in Humans,single-center,open-label, proof-of concept-study to evaluate the safety and tolerability of infusing HSC835 (LFU835-expanded Umbilical Cord hematopoietic stem Cells In patients with hematological malignancies
MT2010-06 KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
COG AALL08B1 - Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
COG ACCL0933 - A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
COG AALL1131 - A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC 606869) in the Very High Risk Stratum Add: AALL1131 Osteonecrosis Sub-study Per Case Reimbursement
MT2012-03: A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
MT2011-05: Multi-Center Phase II Trial of NK Cell Based Non-Myeloablative Haploidentical Transplantation for Patients with High-Risk Acute Myeloid Diseases
HM2012-05: A Phase II Trial Investigating Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
HM2011-04R : Immune Profiling in Myelodysplastic Syndromes and Acute Myeloid Leukemia Myelodysplastic syndrome: Bench to Bedside
Impairments in Cognitive and Cerebral Vascular Function in Cancer Survivors - Development of Methods to Measure Cerebral Vascular Function in Survivors of Childhood Acute Lymphoblastic Leukemia
MT2012-01: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies BMT CTN PROTOCOL 1101
COG ACCL1033 - A Comprehensive Approach to Improving Medication Compliance in Pediatric ALL
MT2013-05R: A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
HM2012-18 Phase III, multicenter, randomized, trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus Cytarabine and Daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML. (CLTR0310-301)
HM2013-12 : IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
MT2012-24R Preparative Regimen Exposure-Response Relationships in Nonmyeloablative Stem Cell Transplants: Correlative Pharmacokinetics.
Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer
Treatment Effects in Children and Adolescent/Young Adults with Leukemia or Lymphoma.
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
COG ADVL1213 - A Phase 1 Study of the TEM-1 Antibody, MORAb-004 (IND#103821), in Children with Recurrent or Refractory Solid Tumors. Additional Title: ADVL1213 - Morphotek, Inc.
COG ADVL1114 - A Phase 1 Study of Temsirolimus (CCI779, IND#61010) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
MT2014-01R Easy-to Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (CTN 1205)
Family-based studies of myeloid disorders and related conditions
MT2013-28R : Positron Emission Tomography (PET) Imaging in Patients with High Risk Hematological Malignancies Receiving Total Body Irradiation (TBI) or Total Marrow Irradiation (TMI) as Part of a Hematopoietic Stem Cell Transplant
BMT Long-Term Follow-up Study -2
MT2006-13 Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)

43 trials displayed

  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on